Treatment of HER2-positive early (minimal) breast cancer
- Authors: Pesotsky R.S.1, Semiglazov V.F1, Tseluyko A.I1, Sokolova M.D1, Mortada V.V1, Tabagua T.T1, Krivorotko P.V1
-
Affiliations:
- N.N. Petrov National Medical Research Center of Oncology
- Issue: Vol 29, No 7 (2022)
- Pages: 43-48
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/321026
- DOI: https://doi.org/10.18565/pharmateca.2022.7.43-48
- ID: 321026
Cite item
Abstract
Full Text
About the authors
Roman S. Pesotsky
N.N. Petrov National Medical Research Center of Oncology
Email: ship-meback@gmail.com
Oncologist, Department of Breast Tumors St. Petersburg, Russia
V. F Semiglazov
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
A. I Tseluyko
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
M. D Sokolova
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
V. V Mortada
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
T. T Tabagua
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
P. V Krivorotko
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
References
- Burstein, H.J., Curigliano, G., Thrlimann, B., et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021 ;32( 10): 1216-35. 10.1016/j.annonc.2021.06.023.
- Gianni L, Semiglazov Eiermann W., et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014:640-47. doi: 10.1016/S1470-2045(14)70080-4.
- Gianni L, Semiglazov V., Manikhas G.M., et al. Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis (abstract 532). J Clin Oncol. 2007;25:532.
- Gianni L, Semiglazov Manikhas G.M., et al. Neoadjuvant trastuzumab plus doxorubicin, paclitaxel and CMF in locally advanced breast cancer (NOAH trial): Feasibility, safety and antitumor effects (abstract 144). ASC Breast Cancer Symposium, 2007.
- Gianni L, Eiermann W., Semiglazov V., et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. 201 0;3 75:377-84. Doi: 10.101 6/S0140- 6736(09)61964-4.
- Capelan M., Pugliano L., De Azambuja E., et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol. 2013;24(2):273-82. doi: 10.1093/annonc/ mds328.
- Gianni L., Pienkowski T., Im, Y.H., et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (‘NeoSphere’) (abstract S3-2). Presented at the 33rd annual San Antonio Breast Cancer Symposium. 2010. December, 8-12. San Antonio: Texas.
- Gianni L., et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (‘NeoSphere') (abstract 1000). Presented at the San Antonio Breast Cancer Symposium. 2010. December, 8-12. San Antonio: Texas.
- Gianni L., et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791-800. doi: 10.1016/S1470-2045(16)00163-7.
- Piccart M., et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. J Clinical Oncol. 2021;39(13):1448-57. doi: 10.1200/JCO.20.01204.
- Ahn E.R., Vogel C.L. Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat. 2012;131:371-83. doi: 10.1007/s10549-011-1781-y.
- Schneeweiss, A., et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278- doi: 10.1093/annonc/mdt182.
- Perez E.A., et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clinical Oncol. 2014;32(33):3744. doi: 10.1200/JCO.2014.55.5730.
- Pivot X., Romieu, G., Debled et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013;14(8):741-48. Doi: 10.1016/ S1470-2045(13)70225-0.
- Hammond M.E., Hayes D.F., Wolff A.C. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol. 2011;29(15):1152-62. doi: 10.1200/JCO.2011.35.2245.
- Slamon D., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-83. Doi: 10.1056/ NEJMoa0910383.
- Salgado R., et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol. 2015;1(4):448-55. doi: 10.1001/jamaoncol.2015.0830.
- Sikov W.M., et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triplenegative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33(1):13. doi: 10.1200/JCO.2014.57.0572.
- Loibl S., et al. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol. 2018;29(12):2341-47. Doi: 10.1093/ annonc/mdy460.
- Gonzalez-Angulo A.M., et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009;27(34):5700. doi: 10.1200/JCO.2009.23.2025.
- Vaz-Luis I., et al. Outcomes by tumor subtype and treatment pattern in women with small, nodenegative breast cancer: a multi-institutional study. J Clin Oncol. 2014;32(20):2142. doi: 10.1200/JCO.2013.53.1608.
- Tolaney S.M., et al. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial. J Clin Oncol. 2021;39(21):2375-85. doi: 10.1200/JCO.20.03398.
- Harbeck N., et al. Primary analysis of KA1TL1N: A phase 111 study of trastuzumab emtansine (T-DM1)+ pertuzumab versus trastuzumab+pertuzumab+ taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC). 2020. J Clin Oncol. doi: 10.1200/JCO.2020.38.15_suppl.500.
- Krop I.E., et al. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase IIIKAITLIN Study. J Clin Oncol. 2022;40(5):438-48. doi: 10.1200/JCO.21.00896.
- Hurvitz S.A., et al. Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study. Lancet Oncol. 2019. doi: 10.1016/S1470-2045(17)30716-7.
- Von Minckwitz G., et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617-28. doi: 10.1056/NEJMoa1814017.
- Cortazar P., Zhang L., Untch M., et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-72. doi: 10.1016/S0140-6736(13)62422-8.